IXC's Principal Activity is the reformulation of Exenatide to optimise the delivery of the drug for patients with IIH, completing regulatory submissions and feedback from global regulatory bodies including the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) on a Phase III clinical trial in IIH, and the prosecution of the Group's patent portfolio.
|Bid / Ask||-|
|Volume (4w avg)|
|vs Sector (1yr)||-28.79%|
|vs ASX 200 (1yr)||-47.10%|
|ASX Rank||1,333 of 2,319|
|Sector Rank||120 of 199|
Invex Therapeutics Ltd (IXC) is a biopharmaceutical company focused on the repurposing of an approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised intracranial pressure, such as Idiopathic Intracranial Hypertension (IIH), acute stroke and traumatic brain injury. Invex has trademarked its repurposed Exenatide as Presendin.
No incorporation details available.
DPS and Yield calculations use the Pay Date.
|Dr Megan Baldwin||Non-Executive Director||Feb 2021||
Dr Megan Baldwin
Dr Baldwin is an experienced biotechnology executive, having over 20 years' experience working on therapeutic drug development programs for cancer and ophthalmic indications. Dr Baldwin is CEO and Managing Director of Opthea Limited (ASX: OPT; NASDAQ: OPT). Under Dr Baldwin's leadership, Opthea has advanced its ophthalmology program through Phase I and Phase II clinical development. It was added to the S&P/ASX 300 in June 2020 and in October 2020 completed initial public offering (IPO) and listing on the US NASDAQ exchange to progress two pivotal Phase III studies in wet AMD. Prior to Opthea, Dr Baldwin was employed at Genentech (now Roche) as a postdoctoral researcher before moving to Genentech's commercial division. Dr Baldwin also serves on the Board of Ausbiotech.
|Dr Thomas (Tom) Duthy||Executive Director||Oct 2020||
Dr Thomas (Tom) Duthy
Dr Duthy has over 15 years of financial markets experience having worked in sell-side equity research, and senior executive roles across investor relations and corporate development. Dr Duthy is the Founder and CEO of Nemean Group Pty Ltd. Prior to establishing Nemean in October 2018, Dr Duthy was the Global Head of Investor Relations & Corporate Development at Sirtex Medical Limited (ASX:SRX). Prior to Sirtex, Tom spent ten years as a leading sell-side Healthcare & Biotechnology analyst at Taylor Collison Limited, focused mainly on small cap companies.
|Dr Alexandra J Sinclair||Chief Scientific Officer,Executive Director||Jun 2019||
Dr Alexandra J Sinclair
Chief Scientific Officer,Executive Director
Dr Sinclair is a Clinician Scientist and Neurology Consultant in the Metabolic Neurology Group at the Institute of Metabolism and Systems Research, College of Medical and Dental Sciences, The University of Birmingham, UK. She runs the Headache service and Idiopathic Intracranial Hypertension Service at University Hospital Foundation Trust. Professor Sinclair is on the MRC Neuroscience and Mental Health Board and the Midland Neuroscience Teaching and Research Fund Board, as well as being Chair of the Brain Research UK Scientific Advisory Board. Previously, she was an elected board member of the IHS and was the Deputy Chair for the Association for British Neurologists grouping for Headache and Pain (ABN AAG). She was on the research committee for the Association for British Neurologists and was also the previous patron of the patient charity IIH UK.
|Mrs Narelle Warren||Chief Financial Officer,Company Secretary||Mar 2019||
Mrs Narelle Warren
Chief Financial Officer,Company Secretary
Ms Warren has over twenty years of corporate advisory, financial management and company secretarial experience. Ms Warren has coordinated and assisted in corporate transactions, including acquisitions, divestments and raising funds via private and public equity markets.
|Mr David McAuliffe||Non-Executive Director||Mar 2019||
Mr David McAuliffe
Mr McAuliffe is an experienced company director and entrepreneur who has had over twenty years' experience, in the international biotechnology field. During that time, he was involved in capital raisings and in-licensing of technologies. He is a founder of several companies in Australia, France and the United Kingdom, many of which have become public companies. Mr McAuliffe is the President of the Dyslexia - Speld Foundation WA (Inc).
|Dr Jason Loveridge||Non-Executive Chairman,Non-Executive Director||Mar 2019||
Dr Jason Loveridge
Non-Executive Chairman,Non-Executive Director
Dr Loveridge is a founder of Invex and also CEO of 4SC AG, a German publicly listed oncology company. He has more than thirty years of international experience across Europe, Asia and the US in senior management positions in life sciences companies and as an investment professional dealing in both privately held and publicly traded companies. Additionally, he has transactional experience in the sale and partnering of biotechnology assets.
IXC directors must report any change in shareholding to the ASX within 5 business days.
See Director Transactions for all ASX companies.
|08/04/21||Megan Baldwin||Issued||400,000||$0.775||$310,000||Issue of options|
|18/11/20||Thomas (Tom) Duthy||Issued||800,000||$0.805||$644,000||Issue of options|
|22/11/19||Alexandra Sinclair||Issued||800,000||$0.71||$568,000||Issue of options|
|22/11/19||David McAuliffe||Issued||200,000||$0.71||$142,000||Issue of options|
|22/11/19||Jason Loveridge||Issued||800,000||$0.71||$568,000||Issue of options|
|22/11/19||Narelle Warren||Issued||400,000||$0.71||$284,000||Issue of options|
The current holdings of IXC directors.
|Director||Last Notice||Direct Shares||Indirect Shares||Options||Convertibles|
|Thomas (Tom) Duthy||27/08/2021||N/A||106,923||800,000||N/A|
A substantial shareholder is a person or entity that owns 5% or more of the voting shares in a company. Shares can be held through multiple entities, so the Substantial Shareholders list differs from the Top 20 Shareholders list.
Shareholding changes less than 1% do not require notification to the market. When all “Last Notice” dates are identical, it suggests that no (or minimal) change has occurred since the most recent Annual Report.
|Name||Last Notice||Total Shares||Shares Held (%)|
|Tattarang Pty Ltd||04/08/2021||8,846,154||11.77|
|Tisia Nominees Pty Ltd||04/08/2021||4,000,000||5.32|
12 month transaction history compiled from ASX announcements.
No buy transactions reported by Substantial Shareholders in the past 12 months.
12 month transaction history compiled from ASX announcements.
|Date||Name||Sold||Previous %||New %|
|01-12-20||JK Nominees Pty Ltd||4,000,000||5.92||--|
All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.